The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

Leukemia
X PapanikolaouB Barlogie

Abstract

As part of Total Therapy (TT) 3b, baseline marrow aspirates were subjected to two-color flow cytometry of nuclear DNA content and cytoplasmic immunoglobulin (DNA/CIG) as well as plasma cell gene expression profiling (GEP). DNA/CIG-derived parameters, GEP and standard clinical variables were examined for their effects on overall survival (OS) and progression-free survival (PFS). Among DNA/CIG parameters, the percentage of the light chain-restricted (LCR) cells and their cytoplasmic immunoglobulin index (CIg) were linked to poor outcome. In the absence of GEP data, low CIg <2.8, albumin <3.5 g/dl and age ⩾65 years were significantly associated with inferior OS and PFS. When GEP information was included, low CIg survived the model along with GEP70-defined high risk and low albumin. Low CIg was linked to beta-2-microglobulin >5.5 mg/l, a percentage of LCR cells exceeding 50%, C-reactive protein ⩾8 mg/l and GEP-derived high centrosome index. Further analysis revealed an association of low CIg with 12 gene probes implicated in cell cycle regulation, differentiation and drug transportation from which a risk score was developed in TT3b that held prognostic significance also in TT3a, TT2 and HOVON trials, thus validating its general app...Continue Reading

References

Mar 8, 1990·The New England Journal of Medicine·J EpsteinX Y He
Aug 1, 1985·The Journal of Clinical Investigation·B BarlogieL Smith
Oct 1, 1984·Cancer Genetics and Cytogenetics·W HiddemannA A Sandberg
Oct 8, 1999·Leukemia & Lymphoma·P R GreippR A Kyle
Nov 28, 2000·International Journal of Cancer. Journal International Du Cancer·T FrisanM G Masucci
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Oct 13, 2001·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·C C ChangD H Vesole
Dec 18, 2001·Cytometry·R P WerstoE Gabrielson
Feb 14, 2003·Current Oncology Reports·W Thomas Purcell, David S Ettinger
Oct 19, 2004·Genome Research·Daniela S GerhardUNKNOWN MGC Project Team
Jan 18, 2006·Annual Review of Medicine·Paul G RichardsonKenneth C Anderson
May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
May 4, 2007·FEBS Letters·Simone Cenci, Roberto Sitia
Oct 3, 2007·PLoS Genetics·Jeffrey T Leek, John D Storey
Oct 24, 2007·The Journal of Cell Biology·Susanne GraserErich A Nigg
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Bart BarlogieJohn Crowley
Apr 17, 2008·Cell Cycle·Emma L DavenportFaith E Davies
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Sep 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kelly BoucherLia E Perez
Dec 18, 2012·Haematologica·Alessandro CampanellaClara Camaschella
Jan 2, 2013·Journal of Cell Science·Nan Tang, Wallace F Marshall
Oct 23, 2013·Cancer Research·Yi-Yuan HuangZhiyuan Shen
Jan 5, 2014·Blood·Ildikó FrigyesiBjörn Nilsson

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE2658

Methods Mentioned

BETA
flow cytometry

Software Mentioned

CellFit
CellQuest

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.